Evidence map›Paper›PMID 40569151›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

KRAS/ABHD17C/ALOX15B Axis Promotes Pancreatic Cancer Progression via Ferroptosis Evasion.

Man Li, Xuexin Yu, Yuanji Liu, Shuqin Ouyang, Long Wu, Xiaohong Chen, Huiqi Yu, Haoming Chen, Senmao Lian, Ziwen Li and 3 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Hypoxia-mediated mJournal of translational medicine · 2025
    Review
  7. Review
  8. KRAS/ABHD17C/ALOX15B Axis Promotes Pancreatic Cancer Progression via Ferroptosis Evasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Man LiState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510080, China.
Xuexin YuDepartment of Biochemistry, Zhongshan School of Medicine Sun Yat-sen University, Guangzhou, 510080, China.
Yuanji LiuDepartment of Biochemistry, Zhongshan School of Medicine Sun Yat-sen University, Guangzhou, 510080, China.
Shuqin OuyangSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510080, China.
Long WuDepartment of Biochemistry and Molecular Biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Xiaohong ChenDepartment of Biochemistry, Zhongshan School of Medicine Sun Yat-sen University, Guangzhou, 510080, China.
Huiqi YuDepartment of Biochemistry, Zhongshan School of Medicine Sun Yat-sen University, Guangzhou, 510080, China.
Haoming ChenDepartment of Biochemistry and Molecular Biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Senmao LianDepartment of Biochemistry and Molecular Biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Ziwen LiDepartment of Biochemistry, Zhongshan School of Medicine Sun Yat-sen University, Guangzhou, 510080, China.
Liyun GongGuangdong Provincial Key Laboratory for Genome Stability and Disease Prevention, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Health Science Center, Shenzhen University, Shenzhen, 518061, China.
Libing SongState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510080, China.
Jun LiState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510080, China.ORCID https://orcid.org/0000-0003-0572-1344

Funding

National Key Research and Development Program of China 2020YFA0509400Natural Science Foundation of China 82030078Natural Science Foundation of China 82330082Natural Science Foundation of China U23A20455Shenzhen Medical Research Fund B2302046
6 · The paper itself

Abstract

Understanding the mechanisms underlying Kirsten rat sarcoma (KRAS) mutation-driven development and progression of pancreatic ductal adenocarcinoma (PDAC) may facilitate the discovery of novel strategies for KRAS-mutant PDAC (KRAS

Indexed as

Arachidonate 15-LipoxygenaseCarcinoma, Pancreatic DuctalFerroptosisPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorDisease ProgressionHumansMaleMiceMutationArachidonate 15-LipoxygenaseKRAS protein, humanProto-Oncogene Proteins p21(ras)ABHD17CALOX15BferroptosisKRAS mutationpancreatic ductal adenocarcinoma

Identifiers

PMID40569151
PMCPMC12463027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.